Abstracts gories: Prospective, Retrospective, Modeling, Quality of Life or Other. A total of 41 retrospective posters were identified through this process, and all were evaluated using a slightly modified ISPOR retrospective checklist (4 criteria were separated into components, yielding a total of 14 points). This checklist helps evaluate the appropriateness of the database, the study design, and the data analysis procedures used. Posters were evaluated by three reviewers to assess compliance with the criteria. RESULTS: The median score was 7 points (out of 14 criteria). The highest score was 11 points and the lowest score was 5 points. More than three-fourths of the posters did not confirm the validity of their data (criterion 2), inclusion/exclusion criteria (criterion 4b), sensitivity analysis for controversial variables (criterion 5b), and the possibility of alternative explanations (criterion 10b). More than half of the posters additionally failed to acknowledge the study design limitations (criterion 3b), describe the method and/or rationale for costing (criterion 6), and control for confounding variables (criterion 7). CONCLUSION: Most of the posters in this convenience sample ranked at the midpoint of the expanded ISPOR checklist. Researchers should pay close attention to the ISPOR checklist when preparing their poster presentations to assure consistently good research practices.
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BEST PRACTICES: EVALUATING MODELING RESEARCH AT ISPOR USING BMJ AND ISPOR GUIDELINES Setyawan J, Patel VD, Nichol MB University of Southern California, Los Angeles, CA, USA OBJECTIVE: To evaluate whether the modeling posters presented at the 2002 ISPOR Seventh Annual International Meeting met the standard of good research practice criteria established by British Medical Journal (BMJ) and ISPOR. METHODS: Posters presented at the meeting were collected onsite or from the ISPOR website. Of the total 337 posters presented, 133 posters (39%) were evaluated. Of the 133 posters collected, 26 were classified as modeling. Nine (9) modeling posters were excluded because they focused exclusively on the denominator or numerator. The remaining 17 posters were evaluated in 3 major sections: a) study design (7 items for BMJ; 3 for ISPOR); b) data validity (14 items for BMJ; 13 for ISPOR); c) analysis and interpretation (14 items for BMJ; 23 for ISPOR). RESULTS: More than half of the posters satisfied 75% or more of the ISPOR and BMJ criteria for study design, and only 5 failed to satisfy at least 50% of the study design criteria. Only six posters satisfied 50% or more of the BMJ data validity criteria, and none of the posters satisfied 50% or more of the ISPOR data validity criteria. More than half of the posters satisfied 50% or more of the BMJ and ISPOR criteria for analysis and interpretation. Posters were slightly more likely to satisfy the BMJ, rather than ISPOR criteria for data validity. Overall, the 17 posters met 51% (18/35) of the BMJ cri-teria and 46% (18/39) of the ISPOR criteria. CONCLU-SIONS: The number of posters reviewed and the number of evaluators limit this study. Reviewed posters revealed satisfactory performance in the study design elements of the ISPOR and BMJ guidelines, but could be improved in data validity and analysis. Generally, the posters performed better when rated using the BMJ rather than the ISPOR guideline.
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PHARMACOEPIDEMIOLGY: A REVIEW OF ITS EMERGING ROLE IN OUTCOMES RESEARCH Richard L Heron Evidence Development Ltd, Stevenage, Hertfordshire, United Kingdom
Pharmacoepidemiology is defined as the application of epidemiological reasoning methods and knowledge to the study of the uses and effects (beneficial and adverse) of drugs in human populations. OBJECTIVES: The purpose of this paper is to review the emerging role of pharmacoepidemiology in outcomes research. METHODS: This review has been based on a systematic literature search using Medline (PubMed), including the abstracts of the International Conference of Pharmacoepidemiolgy since 1990, and a review of core texts recommended by the International Society for Pharmacoepidemiology (ISPE). RESULTS: Three core functions were highlighted by review of the literature. The major role was found to be in the field of pharmacovigilance and its function in phase IV clinical trials or postmarketing surveillance. This was reflected by the predominance of pharmacovigilance abstracts accepted by the ISPE-90% (201/223) of abstracts in 1990 and 72% (222/309) in 2001. Pharmacovigilance, the process of identifying and responding to drug safety issues during phase IV of drug development, is a key requirement of many drug regulatory authorities, including the FDA. Pharmacoepidemiology was also found to play a role in drug utilisation review studies and decision analytic modeling, although its use was found to be less substantial, constituting the balance of the accepted abstracts. CONCLUSION: Although pharmacoepidemiolgy has mainly been used in the field of pharmacovigilance, its use in decision analysis and drug utilisation review was found to be on the increase.
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OPTIMIZING CLINICAL EFFECTIVENESS THROUGH ACTUARIAL MODELING IN HOSPITALS
Vogenberg FR 1 , Weinberg R 1 , Lichtig L 1 , Liebeskind D 1 , Larrat EP 2 1 Aon Consulting, Wellesley, MA, USA; 2 University of Rhode Island College of Pharmacy, Kingston, RI, USA OBJECTIVES: Current data support the use of low molecular weight heparin (LMWH) in lieu of unfractionated heparin (UFH) in many patients to achieve greater clinical efficacy and pharmacoeconomic efficiency. Most hospitals have not achieved clinically effective use of LMWH and UFH in the treatment and prevention of thrombotic disorders. The Clinical Effectiveness Initiative (CEI) was designed to help hospitals achieve better data assessment to measure patient outcomes, reduce medical errors, reduce risk, and reach towards optimal financial performance in these patient groups. METHODS: CEI begins with analysis of data available from the UB-92 and pharmacy or cost-accounting systems. The actuarial analysis provides a risk-adjusted comparison of patient cohorts receiving antithrombotics (LMWH or UFH). Results are reported to the institution in a format suitable for use with performance improvement activities and physicians. The total cost for each cohort is broken down into drug acquisition costs and costs associated with laboratory tests, level of care, supplies and length of stay. RESULTS: Results completed from two hospitals in 87 DRGs that had at least 10 discharges in each drug category (5374 LMWH, 9380 UFH) showed a case mix adjusted average savings of $698 per discharge. The study to-date has showed that the use of LMWH reduced overall cost in many high-use categories, despite the higher drug acquisition cost. Those included DVT, Hip and Knee replacement cases. Findings also demonstrated an opportunity for substantial savings with greater selective use of LMWH in several cohorts that will shared in chart form. The data analysis and structured interviews with hospital leadership presented valuable insights into how best to facilitate changes in practice patterns that can be continually measured. CONCLUSIONS: We conclude that the data assessment and efficiency modeling capabilities of CEI are powerful tools to help hospitals achieve clinical effectiveness, especially when integrated into a hospital's performance improvement program.
PHARMACOECONOMIC & OUTCOMES RESEARCH METHODOLOGY STUDIES-Economic Studies
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DEVELOPING A HEALTH ECONOMIC EVALUATION DATABASE IN JAPAN:
JEED PROJECT Fukuda T, Tsutani K, Kobayashi Y University of Tokyo, Bunkyo, Tokyo, Japan OBJECTIVES: The Japan Economic Evaluation Database (JEED) project aims for critical appraisal of health economic evaluation studies in Japan and build a database with structured abstracts in collaboration with NHS-EED. With careful preparation in 2001, we performed handsearching of all the scientific articles and reports in the health economic fields in Japan in 2002. We analyzed current status of economic evaluation studies and methodological issues. METHODS: Since January 2002, we started to hand-search all articles and reports pub-lished in Japanese journals. Key words for handsearching were types of economic evaluations such as costeffectiveness analysis or cost-utility analysis and methodological terms such as utility score, willingness to pay, QOL measurement and costing. We also adopted words for study areas such as health economic evaluations and pharmacoeconomics. We classified the articles into some categories and picked up methodological issues in Japan. RESULTS: Up to the end of September 2002, we identified 223 articles and reports related to health economic evaluations that appeared in a total of 4881 journals. Most of the articles were general remarks or proceedings. Thirty-four articles out of 233 were classified as original articles, only 6 of which could be identified as full economic evaluations. Nineteen articles were on costing and 4 were on measuring effectiveness or utility. We picked up some issues in economic evaluation studies in Japan. Most of the studies used reimbursement fee though there were some studies for actual costing. Because QOL data for health status were limited in Japanese population, many studies adopted data from foreign countries. There were some articles which did not use terms for economic evaluation studies correctly. CONCLUSIONS: To promote good economic evaluation studies in Japan, systematic critical appraisals and dissemination of information of good studies are needed. We may have to consider methodological guidelines or recommendations for good economic evaluation studies.
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DO DIFFERENCES AMONG COST-EFFECTIVENESS ANALYSIS GUIDELINE RECOMMENDATIONS AFFECT POLICY CONCLUSIONS?
Schackman BR 1 , Gold HT 1 , Stone PW 2 , Neumann PJ 3 1 Weill Medical College of Cornell University, New York, NY, USA; 2 Columbia University School of Nursing, New York, NY, USA; 3 Harvard University, Boston, MA, USA OBJECTIVES: Guidelines for conducting cost-utility analyses (CUAs) contain inconsistent recommendations for selecting cost, quality of life, and discount rate parameters. Sensitivity analyses can indicate whether adhering to different guidelines results in different policy recommendations. The purpose of this study is to investigate the use of sensitivity analyses to test economic parameters in the cost-utility literature. METHODS: Recommendations from published guidelines are summarized. CUAs of pharmaceutical therapies identified in a prior study (N = 71 articles) were reviewed and further audited. We identified threshold CU ratios (N = 36) and base cases for which sensitivity analyses were reported (N = 123). For each base case, up to 2 sensitivity analyses for cost (N = 97), quality of life (N = 136), and discount rate (N = 127) were examined. RESULTS: There are substantial disagreements among the guidelines regarding economic parameters. The most frequently mentioned threshold CU ratios were $20,000/QALY, $50,000/
